Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases

Laura Räisänen; Heli Viljakainen; Kaija-Leena Kolho

doi:10.3389/fped.2023.1157547

Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases

Front Pediatr. 2023 Mar 27:11:1157547. doi: 10.3389/fped.2023.1157547. eCollection 2023.

Authors

Laura Räisänen¹, Heli Viljakainen^{2

3}, Kaija-Leena Kolho^{3

4}

Affiliations

¹ Department of Pediatrics, Tampere University Hospital, Tampere, Finland.
² Public Health Research Program, Folkhälsan Research Center, Helsinki, Finland.
³ Children's Hospital, University of Helsinki and HUS, Helsinki, Finland.
⁴ Faculty of Medicine and Medical Technology, Tampere University, Tampere, Finland.

Abstract

Proton pump inhibitors (PPIs) have been associated with decreased gut microbiota diversity. Disrupted gut microbiota composition has been reported in several autoimmune diseases (ADs), such as type 1 diabetes mellitus (DM), autoimmune thyroiditis (AIT), juvenile idiopathic arthritis (JIA), and inflammatory bowel diseases (IBD). We investigated whether PPIs are associated with the development of ADs in children and concluded that PPI exposures could be related to the onset of ADs, especially IBD and potentially AIT as well.

Keywords: autoimmune thyroiditis; inflammatory bowel diseases; juvenile idiopathic arthritis; omeprazole; type 1 diabetes mellitus.

Grants and funding

This research is supported by the Finnish government's research fund (VTR_2022, grant number 9AC086 to LR).